Incidence, Clinical Features, and Prognostic Impact of CALR Exon 9 Mutations in Essential Thrombocythemia and Primary Myelofibrosis: An Experience of a Single Tertiary Hospital in Korea
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
We evaluated the incidence, clinical characteristics, and prognostic impact of calreticulin (CALR) mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients. In all, 48 ET and 14 PMF patients were enrolled, and the presence of CALR mutations was analyzed by direct sequencing. Patients were classified into three subgroups according to Janus kinase 2 (JAK2) V617F and CALR mutation status, and their clinical features and prognosis were compared. CALR mutations were detected in 15 (24.2%) patients, and the incidence increased to 50.0% in 30 JAK2 V617F mutation-negative cases. These included 11 patients with three known mutations (c.1092_1143del [seven cases], c.1154_1155insTTGTC [three cases], and c.1102_1135del [one case]) and 4 patients with novel mutations. ET patients carrying CALR mutation were younger, had lower white blood cell counts, and experienced less thrombosis during follow-up than those carrying JAK2 V617F mutation, while both patient groups showed similar clinical features and prognosis. In ET patients without JAK2 V617F mutation, CALR mutation did not significantly affect clinical manifestation and prognosis. In conclusion, CALR mutation analysis could be a useful diagnostic tool for ET and PMF in 50% of the cases without JAK2 V617F mutations. The prognostic impact of CALR mutations needs further investigation.
Abstract
We evaluated the incidence, clinical characteristics, and prognostic impact of calreticulin (CALR) mutations in essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients. In all, 48 ET and 14 PMF patients were enrolled, and the presence of CALR mutations was analyzed by direct sequencing. Patients were classified into three subgroups according to Janus kinase 2 (JAK2) V617F and CALR mutation status, and their clinical features and prognosis were compared. CALR mutations were detected in 15 (24.2%) patients, and the incidence increased to 50.0% in 30 JAK2 V617F mutation-negative cases. These included 11 patients with three known mutations (c.1092_1143del [seven cases], c.1154_1155insTTGTC [three cases], and c.1102_1135del [one case]) and 4 patients with novel mutations. ET patients carrying CALR mutation were younger, had lower white blood cell counts, and experienced less thrombosis during follow-up than those carrying JAK2 V617F mutation, while both patient groups showed similar clinical features and prognosis. In ET patients without JAK2 V617F mutation, CALR mutation did not significantly affect clinical manifestation and prognosis. In conclusion, CALR mutation analysis could be a useful diagnostic tool for ET and PMF in 50% of the cases without JAK2 V617F mutations. The prognostic impact of CALR mutations needs further investigation.
참고문헌 (20)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2008), IARC
- Scott LM, "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis", N Engl J Med, 356, pp.459~468 (2007)
- Butcher CM, "Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients", Leukemia, 22, pp.870~873 (2008)
- Campbell PJ, "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study", Lancet, 366, pp.1945~1953 (2005)
- Campbell PJ, "V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis", Blood, 107, pp.2098~2100 (2006)
- Bench AJ, "Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations", Br J Haematol, 160, pp.25~34 (2013)
- Passamonti F, "Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations", Blood, 117, pp.2813~2816 (2011)
- Rumi E, "Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms", Blood, 121, pp.4388~4395 (2013)
- Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)
- Rumi E, "JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes", Blood, 123, pp.1544~1551 (2014)
- Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons", Leukemia, 28, pp.1472~1477 (2014)
- Tefferi A, "CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients", Leukemia, 28, pp.1494~1500 (2014)
- Rumi E, "CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis", Blood, 123, pp.2416~2419 (2014)
- Gangat N, "Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history", Eur J Haematol (2014)[DOI]
- Nangalia J, "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2", N Engl J Med, 369, pp.2391~2405 (2013)
- Tefferi A, "An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms", Leukemia, 28, pp.1407~1413 (2014)
- Li B, "Calreticulin mutations in Chinese with primary myelofibrosis", Haematologica, 99, pp.1697~1700 (2014)
- Shen H, "CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia", Leuk Lymphoma, 13, pp.1~3 (2014)
- Chen CC, "Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia", Ann Hematol (2014)
- Passamonti F, "A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)", Blood, 115, pp.1703~1708 (2010)